



Seamless robotic surgery

enabling easier, less invasive and cost effective procedures



Investment highlights



Multi-billion dollar Market

Growing surgical robotics market for various indications



Answering surgical unmet needs

The smallest & farthest reaching surgical robot



Multiple applications

in trans-vaginal, umbilical and multiport approach



Powerful IP portfolio

Over 50 patents in robotic technology, surgical methods and procedures



Clinical and regulatory status

FIH in vaginal access
FDA 510K pathway




World-renowned KOLs

Endorsing numerous usability tests in various indications

Introducing Hominis™

The smallest, farthest reaching surgical robot

small and flexible enough to enable surgical procedures otherwise considered as unfeasible.



It's unique design enables superior surgical and ergonomics capabilities, while keeping cost and footprint to a minimum.

Breaking anatomical barriers with Hominis™

Unprecedented maneuverability

Humanoid Articulation (360°)




Existing robots have limited maneuverability:

- Fulcrum movements + Wrist
- Less than 90°, no retro-flexion

Untapped Access

Multi-port & single port (abdominal)

Trans vaginal



Existing robots are single or multi port only.

The case of vaginal hysterectomy

“**Vaginal** minimally invasive approaches to hysterectomy should be performed, **whenever feasible**, over abdominal and laparoscopic hysterectomy¹”

The American College of
Obstetricians & Gynecologists



Faster recoveries



Better patient satisfaction




Lower overall costs

Yet they are feasible in only 15% of cases
due to anatomical barriers


Hominis™ is the **ONLY** robot to enable the vaginal approach

Breaking the 15% barrier to majority of population

Patented
surgical
method and
device




Hominis™ patented
vaginal hysterectomy



Investment sought

Round Structure

\$10M, Pre-money valuation of **\$50M**
(divided into two tranches)



Investment Shares

Series C-1

Preferred Shares
issued at first tranche

Series C-2

Preferred Shares
issued at second
tranche

- Only difference between the two classes is the **price per share** (based on different valuations)
- Shares have the same rights as other Preferred Shares of Company with preference over other Preferred Shares in distributions



Thank You.

Dvir Cohen, CEO
dvirco@memicmed.com